Security Snapshot

Travere Therapeutics, Inc. - Common Stock (TVTX) Institutional Ownership

CUSIP: 89422G107

13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

262

Shares (Excl. Options)

83.63MFull value: 83,627,111 · shares · 30 Sep 2026

Price

$58.88

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+5,187,905
Value change
+$306,287,413
Number of holders
262
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
95,925,423
SEC-reported price per share
$50.88
Insider filing price
$50.88
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TVTX - Travere Therapeutics, Inc. - Common Stock is tracked under CUSIP 89422G107.
  • 262 institutions reported positions in Q3 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 317 to 262 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $5.98BFull value: $5,978,334,365 · USD · 30 Jun 2026
    to
    $4.92BFull value: $4,922,472,601 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 262 institutions filings for Q3 2026.

Open SEC evidence

Security key

89422G107

13F reference period

Q3 2026

13F holders

262

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
TVTX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12% -6.9% $253,331,874 -$17,690,876 10,599,660 -6.5% JANUS HENDERSON GROUP PLC 30 Sep 2025
BANK OF AMERICA CORP /DE/ 7.1% +22% $354,292,874 +$71,348,031 6,810,705 +25% BANK OF AMERICA CORP /DE/ 30 Sep 2026
BlackRock, Inc. 7.5% -21% $122,617,344 -$24,357,949 6,689,435 -17% BlackRock, Inc. 31 Mar 2025
FMR LLC 6.1% -20% $296,924,081 -$74,627,840 5,707,883 -20% FMR LLC 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.1% $139,619,887 4,699,424 Vanguard Capital Management 31 Mar 2026
PERCEPTIVE ADVISORS LLC 4.8% -12% $124,537,820 -$17,973,533 4,278,180 -13% Perceptive Advisors LLC 31 Dec 2025
STATE STREET CORP 4.6% -14% $244,647,756 -$28,765,406 4,256,224 -11% STATE STREET CORPORATION 30 Jun 2026
Rock Springs Capital Management LP 3.3% -40% $53,545,523 -$37,621,463 2,921,196 -41% Rock Springs Capital Management LP 31 Mar 2025
Woodline Partners LP 2.4% $38,750,646 2,114,056 Woodline Partners LP 31 Dec 2024
ARMISTICE CAPITAL, LLC 1.7% -72% $90,389,542 -$191,113,987 1,572,539 -68% Armistice Capital, LLC 30 Jun 2026
As of 30 Sep 2026, 262 institutional investors reported holding
83.63MFull value: 83,627,111 · shares · 30 Sep 2026
shares of Travere Therapeutics, Inc. - Common Stock (TVTX). This represents 87% of the company’s total
95.93MFull value: 95,925,423 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
65%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Janus Henderson Group Ltd. 12% 11,891,480 0.3% $700,058,180
BANK OF AMERICA CORP /DE/ 6.1% 5,824,254 0.02% $342,932,099
STATE STREET CORP 4.6% 4,387,309 0.01% $258,324,754
VANGUARD CAPITAL MANAGEMENT LLC 4.4% 4,192,887 0.01% $246,877,187
PERCEPTIVE ADVISORS LLC 3.7% 3,542,913 3.9% $208,606,717
VANGUARD PORTFOLIO MANAGEMENT LLC 3.2% 3,040,158 0.01% $179,004,503
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,420,340 0.01% $142,537,650
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.5% 2,410,485 0.2% $141,929,357
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 2.3% 2,239,948 0.21% $131,888,138
Rock Springs Capital Management LP 2.3% 2,204,085 7% $129,776,525
Kynam Capital Management, LP 2.1% 2,000,000 6.5% $117,760,000
Stephens Investment Management Group LLC 2% 1,876,683 1.2% $110,499,095
GOLDMAN SACHS GROUP INC 1.9% 1,806,696 0.01% $106,378,291
WELLINGTON MANAGEMENT GROUP LLP 1.6% 1,579,139 0.02% $92,979,703
EMERALD ADVISERS, LLC 1.6% 1,563,532 2.5% $92,060,764
Driehaus Capital Management LLC 1.6% 1,533,171 0.63% $90,273,108
ARMISTICE CAPITAL, LLC 1.3% 1,289,768 2.5% $75,941,540
ORBIMED ADVISORS LLC 1.3% 1,200,425 1.3% $70,681,024
Qube Research & Technologies Ltd 1.2% 1,171,448 0.07% $68,974,858
Assenagon Asset Management S.A. 1.2% 1,145,414 0.07% $67,441,976
MPM BIOIMPACT LLC 1.1% 1,088,363 4.9% $64,082,813
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,078,079 0.09% $63,477,292
EMERALD MUTUAL FUND ADVISERS TRUST 1% 984,847 2.4% $57,987,791
MARSHALL WACE, LLP 1% 978,220 0.05% $57,597,590
Jones Hill Capital LP 1% 959,634 9.6% $56,503,250

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Headline period
Q3 2026
Rows shown
1-24 of 24
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 83,627,111 $4,922,472,601 +$306,287,413 $58.88 262
2026 Q2 105,273,422 $5,978,334,365 +$226,591,815 $56.81 317
2026 Q1 101,374,245 $3,011,081,509 -$45,650,139 $29.71 260
2025 Q4 102,162,218 $3,903,903,645 +$7,451,854 $38.21 276
2025 Q3 100,727,863 $2,407,390,168 +$19,761,610 $23.90 235
2025 Q2 100,531,635 $1,487,836,300 +$12,972,115 $14.80 207
2025 Q1 98,007,579 $1,771,747,554 +$87,075,624 $17.92 214
2024 Q4 95,064,656 $1,655,970,325 +$204,069,962 $17.42 194
2024 Q3 82,734,245 $1,157,476,987 -$64,293,173 $13.99 175
2024 Q2 87,955,117 $723,000,948 +$2,540,410 $8.22 168
2024 Q1 87,706,388 $676,170,447 +$11,374,907 $7.71 172
2023 Q4 85,573,515 $769,316,791 +$27,493,568 $8.99 162
2023 Q3 82,430,217 $736,935,857 -$48,196,261 $8.94 166
2023 Q2 82,714,633 $1,270,488,775 -$85,984,898 $15.36 165
2023 Q1 84,151,882 $1,892,538,812 +$263,849,900 $22.49 171
2022 Q4 72,978,794 $1,535,405,782 +$36,464,951 $21.03 153
2022 Q3 69,779,173 $1,719,469,986 -$2,015,044 $24.64 168
2022 Q2 69,489,567 $1,683,983,339 +$17,370,839 $24.23 166
2022 Q1 69,479,485 $1,789,961,946 +$97,223,694 $25.77 166
2021 Q4 65,477,167 $2,032,139,426 +$61,452,684 $31.04 165
2021 Q3 60,858,590 $1,476,104,164 +$4,235,576 $24.25 145
2021 Q2 60,583,594 $883,983,031 -$73,514,650 $14.59 131
2021 Q1 62,621,768 $1,563,390,183 +$254,685,025 $24.97 147
2020 Q4 52,293,956 $1,423,328,983 +$1,416,953,984 $27.26 135
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .